ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Endogenous Peptide Substances Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-25Q15542
Home | Market Reports | Science| Biological Sciences
Global Endogenous Peptide Substances Market Research Report 2023
BUY CHAPTERS

Global Endogenous Peptide Substances Market Research Report 2025

Code: QYRE-Auto-25Q15542
Report
May 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc
Endo International Plc.
Biosynth Carbosynth
Lannett Co Inc
Pfizer Inc
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides

Endogenous Peptide Substances Market

The global market for Endogenous Peptide Substances was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The driving force of endogenous peptides mainly comes from the following aspects:
Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and development: With the development of medical technology, people"s demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
This report aims to provide a comprehensive presentation of the global market for Endogenous Peptide Substances, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endogenous Peptide Substances.
The Endogenous Peptide Substances market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Endogenous Peptide Substances market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Endogenous Peptide Substances companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Endogenous Peptide Substances Market Report

Report Metric Details
Report Name Endogenous Peptide Substances Market
Segment by Type
  • Neuropeptides
  • Hormones
  • Cytokines
  • Peptide Hormones
  • Bioactive Peptides
Segment by Application
  • Research
  • Medicine
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Assertio Therapeutics Inc., Cipher Pharmaceuticals Inc., Endo International Plc, Biosynth Carbosynth, Lannett Co. Inc., Pfizer, Johnson & Johnson, Peptide Institute, Abbexa, Phoenix Pharmaceuticals, Creative Peptides
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Endogenous Peptide Substances company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Endogenous Peptide Substances Market report?

Ans: The main players in the Endogenous Peptide Substances Market are Assertio Therapeutics Inc., Cipher Pharmaceuticals Inc., Endo International Plc, Biosynth Carbosynth, Lannett Co. Inc., Pfizer, Johnson & Johnson, Peptide Institute, Abbexa, Phoenix Pharmaceuticals, Creative Peptides

What are the Application segmentation covered in the Endogenous Peptide Substances Market report?

Ans: The Applications covered in the Endogenous Peptide Substances Market report are Research, Medicine, Others

What are the Type segmentation covered in the Endogenous Peptide Substances Market report?

Ans: The Types covered in the Endogenous Peptide Substances Market report are Neuropeptides, Hormones, Cytokines, Peptide Hormones, Bioactive Peptides

Recommended Reports

Peptide Drug Markets

Hormones and Endocrine

Bioactive & Collagen Peptides

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Endogenous Peptide Substances Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Neuropeptides
1.2.3 Hormones
1.2.4 Cytokines
1.2.5 Peptide Hormones
1.2.6 Bioactive Peptides
1.3 Market by Application
1.3.1 Global Endogenous Peptide Substances Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Research
1.3.3 Medicine
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Endogenous Peptide Substances Market Perspective (2020-2031)
2.2 Global Endogenous Peptide Substances Growth Trends by Region
2.2.1 Global Endogenous Peptide Substances Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Endogenous Peptide Substances Historic Market Size by Region (2020-2025)
2.2.3 Endogenous Peptide Substances Forecasted Market Size by Region (2026-2031)
2.3 Endogenous Peptide Substances Market Dynamics
2.3.1 Endogenous Peptide Substances Industry Trends
2.3.2 Endogenous Peptide Substances Market Drivers
2.3.3 Endogenous Peptide Substances Market Challenges
2.3.4 Endogenous Peptide Substances Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Endogenous Peptide Substances Players by Revenue
3.1.1 Global Top Endogenous Peptide Substances Players by Revenue (2020-2025)
3.1.2 Global Endogenous Peptide Substances Revenue Market Share by Players (2020-2025)
3.2 Global Endogenous Peptide Substances Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Endogenous Peptide Substances Revenue
3.4 Global Endogenous Peptide Substances Market Concentration Ratio
3.4.1 Global Endogenous Peptide Substances Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Endogenous Peptide Substances Revenue in 2024
3.5 Global Key Players of Endogenous Peptide Substances Head office and Area Served
3.6 Global Key Players of Endogenous Peptide Substances, Product and Application
3.7 Global Key Players of Endogenous Peptide Substances, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Endogenous Peptide Substances Breakdown Data by Type
4.1 Global Endogenous Peptide Substances Historic Market Size by Type (2020-2025)
4.2 Global Endogenous Peptide Substances Forecasted Market Size by Type (2026-2031)
5 Endogenous Peptide Substances Breakdown Data by Application
5.1 Global Endogenous Peptide Substances Historic Market Size by Application (2020-2025)
5.2 Global Endogenous Peptide Substances Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Endogenous Peptide Substances Market Size (2020-2031)
6.2 North America Endogenous Peptide Substances Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Endogenous Peptide Substances Market Size by Country (2020-2025)
6.4 North America Endogenous Peptide Substances Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Endogenous Peptide Substances Market Size (2020-2031)
7.2 Europe Endogenous Peptide Substances Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Endogenous Peptide Substances Market Size by Country (2020-2025)
7.4 Europe Endogenous Peptide Substances Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Endogenous Peptide Substances Market Size (2020-2031)
8.2 Asia-Pacific Endogenous Peptide Substances Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Endogenous Peptide Substances Market Size by Region (2020-2025)
8.4 Asia-Pacific Endogenous Peptide Substances Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Endogenous Peptide Substances Market Size (2020-2031)
9.2 Latin America Endogenous Peptide Substances Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Endogenous Peptide Substances Market Size by Country (2020-2025)
9.4 Latin America Endogenous Peptide Substances Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Endogenous Peptide Substances Market Size (2020-2031)
10.2 Middle East & Africa Endogenous Peptide Substances Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Endogenous Peptide Substances Market Size by Country (2020-2025)
10.4 Middle East & Africa Endogenous Peptide Substances Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Assertio Therapeutics Inc.
11.1.1 Assertio Therapeutics Inc. Company Details
11.1.2 Assertio Therapeutics Inc. Business Overview
11.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Introduction
11.1.4 Assertio Therapeutics Inc. Revenue in Endogenous Peptide Substances Business (2020-2025)
11.1.5 Assertio Therapeutics Inc. Recent Development
11.2 Cipher Pharmaceuticals Inc.
11.2.1 Cipher Pharmaceuticals Inc. Company Details
11.2.2 Cipher Pharmaceuticals Inc. Business Overview
11.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Introduction
11.2.4 Cipher Pharmaceuticals Inc. Revenue in Endogenous Peptide Substances Business (2020-2025)
11.2.5 Cipher Pharmaceuticals Inc. Recent Development
11.3 Endo International Plc
11.3.1 Endo International Plc Company Details
11.3.2 Endo International Plc Business Overview
11.3.3 Endo International Plc Endogenous Peptide Substances Introduction
11.3.4 Endo International Plc Revenue in Endogenous Peptide Substances Business (2020-2025)
11.3.5 Endo International Plc Recent Development
11.4 Biosynth Carbosynth
11.4.1 Biosynth Carbosynth Company Details
11.4.2 Biosynth Carbosynth Business Overview
11.4.3 Biosynth Carbosynth Endogenous Peptide Substances Introduction
11.4.4 Biosynth Carbosynth Revenue in Endogenous Peptide Substances Business (2020-2025)
11.4.5 Biosynth Carbosynth Recent Development
11.5 Lannett Co. Inc.
11.5.1 Lannett Co. Inc. Company Details
11.5.2 Lannett Co. Inc. Business Overview
11.5.3 Lannett Co. Inc. Endogenous Peptide Substances Introduction
11.5.4 Lannett Co. Inc. Revenue in Endogenous Peptide Substances Business (2020-2025)
11.5.5 Lannett Co. Inc. Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Endogenous Peptide Substances Introduction
11.6.4 Pfizer Revenue in Endogenous Peptide Substances Business (2020-2025)
11.6.5 Pfizer Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Endogenous Peptide Substances Introduction
11.7.4 Johnson & Johnson Revenue in Endogenous Peptide Substances Business (2020-2025)
11.7.5 Johnson & Johnson Recent Development
11.8 Peptide Institute
11.8.1 Peptide Institute Company Details
11.8.2 Peptide Institute Business Overview
11.8.3 Peptide Institute Endogenous Peptide Substances Introduction
11.8.4 Peptide Institute Revenue in Endogenous Peptide Substances Business (2020-2025)
11.8.5 Peptide Institute Recent Development
11.9 Abbexa
11.9.1 Abbexa Company Details
11.9.2 Abbexa Business Overview
11.9.3 Abbexa Endogenous Peptide Substances Introduction
11.9.4 Abbexa Revenue in Endogenous Peptide Substances Business (2020-2025)
11.9.5 Abbexa Recent Development
11.10 Phoenix Pharmaceuticals
11.10.1 Phoenix Pharmaceuticals Company Details
11.10.2 Phoenix Pharmaceuticals Business Overview
11.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Introduction
11.10.4 Phoenix Pharmaceuticals Revenue in Endogenous Peptide Substances Business (2020-2025)
11.10.5 Phoenix Pharmaceuticals Recent Development
11.11 Creative Peptides
11.11.1 Creative Peptides Company Details
11.11.2 Creative Peptides Business Overview
11.11.3 Creative Peptides Endogenous Peptide Substances Introduction
11.11.4 Creative Peptides Revenue in Endogenous Peptide Substances Business (2020-2025)
11.11.5 Creative Peptides Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc
Endo International Plc.
Biosynth Carbosynth
Lannett Co Inc
Pfizer Inc
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides
List of Tables
 Table 1. Global Endogenous Peptide Substances Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Neuropeptides
 Table 3. Key Players of Hormones
 Table 4. Key Players of Cytokines
 Table 5. Key Players of Peptide Hormones
 Table 6. Key Players of Bioactive Peptides
 Table 7. Global Endogenous Peptide Substances Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Endogenous Peptide Substances Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Endogenous Peptide Substances Market Size by Region (2020-2025) & (US$ Million)
 Table 10. Global Endogenous Peptide Substances Market Share by Region (2020-2025)
 Table 11. Global Endogenous Peptide Substances Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 12. Global Endogenous Peptide Substances Market Share by Region (2026-2031)
 Table 13. Endogenous Peptide Substances Market Trends
 Table 14. Endogenous Peptide Substances Market Drivers
 Table 15. Endogenous Peptide Substances Market Challenges
 Table 16. Endogenous Peptide Substances Market Restraints
 Table 17. Global Endogenous Peptide Substances Revenue by Players (2020-2025) & (US$ Million)
 Table 18. Global Endogenous Peptide Substances Market Share by Players (2020-2025)
 Table 19. Global Top Endogenous Peptide Substances Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endogenous Peptide Substances as of 2024)
 Table 20. Ranking of Global Top Endogenous Peptide Substances Companies by Revenue (US$ Million) in 2024
 Table 21. Global 5 Largest Players Market Share by Endogenous Peptide Substances Revenue (CR5 and HHI) & (2020-2025)
 Table 22. Global Key Players of Endogenous Peptide Substances, Headquarters and Area Served
 Table 23. Global Key Players of Endogenous Peptide Substances, Product and Application
 Table 24. Global Key Players of Endogenous Peptide Substances, Date of Enter into This Industry
 Table 25. Mergers & Acquisitions, Expansion Plans
 Table 26. Global Endogenous Peptide Substances Market Size by Type (2020-2025) & (US$ Million)
 Table 27. Global Endogenous Peptide Substances Revenue Market Share by Type (2020-2025)
 Table 28. Global Endogenous Peptide Substances Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 29. Global Endogenous Peptide Substances Revenue Market Share by Type (2026-2031)
 Table 30. Global Endogenous Peptide Substances Market Size by Application (2020-2025) & (US$ Million)
 Table 31. Global Endogenous Peptide Substances Revenue Market Share by Application (2020-2025)
 Table 32. Global Endogenous Peptide Substances Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 33. Global Endogenous Peptide Substances Revenue Market Share by Application (2026-2031)
 Table 34. North America Endogenous Peptide Substances Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. North America Endogenous Peptide Substances Market Size by Country (2020-2025) & (US$ Million)
 Table 36. North America Endogenous Peptide Substances Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Europe Endogenous Peptide Substances Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Europe Endogenous Peptide Substances Market Size by Country (2020-2025) & (US$ Million)
 Table 39. Europe Endogenous Peptide Substances Market Size by Country (2026-2031) & (US$ Million)
 Table 40. Asia-Pacific Endogenous Peptide Substances Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Asia-Pacific Endogenous Peptide Substances Market Size by Region (2020-2025) & (US$ Million)
 Table 42. Asia-Pacific Endogenous Peptide Substances Market Size by Region (2026-2031) & (US$ Million)
 Table 43. Latin America Endogenous Peptide Substances Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Latin America Endogenous Peptide Substances Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Latin America Endogenous Peptide Substances Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Middle East & Africa Endogenous Peptide Substances Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 47. Middle East & Africa Endogenous Peptide Substances Market Size by Country (2020-2025) & (US$ Million)
 Table 48. Middle East & Africa Endogenous Peptide Substances Market Size by Country (2026-2031) & (US$ Million)
 Table 49. Assertio Therapeutics Inc. Company Details
 Table 50. Assertio Therapeutics Inc. Business Overview
 Table 51. Assertio Therapeutics Inc. Endogenous Peptide Substances Product
 Table 52. Assertio Therapeutics Inc. Revenue in Endogenous Peptide Substances Business (2020-2025) & (US$ Million)
 Table 53. Assertio Therapeutics Inc. Recent Development
 Table 54. Cipher Pharmaceuticals Inc. Company Details
 Table 55. Cipher Pharmaceuticals Inc. Business Overview
 Table 56. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product
 Table 57. Cipher Pharmaceuticals Inc. Revenue in Endogenous Peptide Substances Business (2020-2025) & (US$ Million)
 Table 58. Cipher Pharmaceuticals Inc. Recent Development
 Table 59. Endo International Plc Company Details
 Table 60. Endo International Plc Business Overview
 Table 61. Endo International Plc Endogenous Peptide Substances Product
 Table 62. Endo International Plc Revenue in Endogenous Peptide Substances Business (2020-2025) & (US$ Million)
 Table 63. Endo International Plc Recent Development
 Table 64. Biosynth Carbosynth Company Details
 Table 65. Biosynth Carbosynth Business Overview
 Table 66. Biosynth Carbosynth Endogenous Peptide Substances Product
 Table 67. Biosynth Carbosynth Revenue in Endogenous Peptide Substances Business (2020-2025) & (US$ Million)
 Table 68. Biosynth Carbosynth Recent Development
 Table 69. Lannett Co. Inc. Company Details
 Table 70. Lannett Co. Inc. Business Overview
 Table 71. Lannett Co. Inc. Endogenous Peptide Substances Product
 Table 72. Lannett Co. Inc. Revenue in Endogenous Peptide Substances Business (2020-2025) & (US$ Million)
 Table 73. Lannett Co. Inc. Recent Development
 Table 74. Pfizer Company Details
 Table 75. Pfizer Business Overview
 Table 76. Pfizer Endogenous Peptide Substances Product
 Table 77. Pfizer Revenue in Endogenous Peptide Substances Business (2020-2025) & (US$ Million)
 Table 78. Pfizer Recent Development
 Table 79. Johnson & Johnson Company Details
 Table 80. Johnson & Johnson Business Overview
 Table 81. Johnson & Johnson Endogenous Peptide Substances Product
 Table 82. Johnson & Johnson Revenue in Endogenous Peptide Substances Business (2020-2025) & (US$ Million)
 Table 83. Johnson & Johnson Recent Development
 Table 84. Peptide Institute Company Details
 Table 85. Peptide Institute Business Overview
 Table 86. Peptide Institute Endogenous Peptide Substances Product
 Table 87. Peptide Institute Revenue in Endogenous Peptide Substances Business (2020-2025) & (US$ Million)
 Table 88. Peptide Institute Recent Development
 Table 89. Abbexa Company Details
 Table 90. Abbexa Business Overview
 Table 91. Abbexa Endogenous Peptide Substances Product
 Table 92. Abbexa Revenue in Endogenous Peptide Substances Business (2020-2025) & (US$ Million)
 Table 93. Abbexa Recent Development
 Table 94. Phoenix Pharmaceuticals Company Details
 Table 95. Phoenix Pharmaceuticals Business Overview
 Table 96. Phoenix Pharmaceuticals Endogenous Peptide Substances Product
 Table 97. Phoenix Pharmaceuticals Revenue in Endogenous Peptide Substances Business (2020-2025) & (US$ Million)
 Table 98. Phoenix Pharmaceuticals Recent Development
 Table 99. Creative Peptides Company Details
 Table 100. Creative Peptides Business Overview
 Table 101. Creative Peptides Endogenous Peptide Substances Product
 Table 102. Creative Peptides Revenue in Endogenous Peptide Substances Business (2020-2025) & (US$ Million)
 Table 103. Creative Peptides Recent Development
 Table 104. Research Programs/Design for This Report
 Table 105. Key Data Information from Secondary Sources
 Table 106. Key Data Information from Primary Sources
 Table 107. Authors List of This Report


List of Figures
 Figure 1. Endogenous Peptide Substances Picture
 Figure 2. Global Endogenous Peptide Substances Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Endogenous Peptide Substances Market Share by Type: 2024 VS 2031
 Figure 4. Neuropeptides Features
 Figure 5. Hormones Features
 Figure 6. Cytokines Features
 Figure 7. Peptide Hormones Features
 Figure 8. Bioactive Peptides Features
 Figure 9. Global Endogenous Peptide Substances Market Size by Application (2020-2031) & (US$ Million)
 Figure 10. Global Endogenous Peptide Substances Market Share by Application: 2024 VS 2031
 Figure 11. Research Case Studies
 Figure 12. Medicine Case Studies
 Figure 13. Others Case Studies
 Figure 14. Endogenous Peptide Substances Report Years Considered
 Figure 15. Global Endogenous Peptide Substances Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global Endogenous Peptide Substances Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Endogenous Peptide Substances Market Share by Region: 2024 VS 2031
 Figure 18. Global Endogenous Peptide Substances Market Share by Players in 2024
 Figure 19. Global Top Endogenous Peptide Substances Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endogenous Peptide Substances as of 2024)
 Figure 20. The Top 10 and 5 Players Market Share by Endogenous Peptide Substances Revenue in 2024
 Figure 21. North America Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America Endogenous Peptide Substances Market Share by Country (2020-2031)
 Figure 23. United States Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Endogenous Peptide Substances Market Share by Country (2020-2031)
 Figure 27. Germany Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Endogenous Peptide Substances Market Share by Region (2020-2031)
 Figure 35. China Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Endogenous Peptide Substances Market Share by Country (2020-2031)
 Figure 43. Mexico Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Endogenous Peptide Substances Market Share by Country (2020-2031)
 Figure 47. Turkey Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE Endogenous Peptide Substances Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Assertio Therapeutics Inc. Revenue Growth Rate in Endogenous Peptide Substances Business (2020-2025)
 Figure 51. Cipher Pharmaceuticals Inc. Revenue Growth Rate in Endogenous Peptide Substances Business (2020-2025)
 Figure 52. Endo International Plc Revenue Growth Rate in Endogenous Peptide Substances Business (2020-2025)
 Figure 53. Biosynth Carbosynth Revenue Growth Rate in Endogenous Peptide Substances Business (2020-2025)
 Figure 54. Lannett Co. Inc. Revenue Growth Rate in Endogenous Peptide Substances Business (2020-2025)
 Figure 55. Pfizer Revenue Growth Rate in Endogenous Peptide Substances Business (2020-2025)
 Figure 56. Johnson & Johnson Revenue Growth Rate in Endogenous Peptide Substances Business (2020-2025)
 Figure 57. Peptide Institute Revenue Growth Rate in Endogenous Peptide Substances Business (2020-2025)
 Figure 58. Abbexa Revenue Growth Rate in Endogenous Peptide Substances Business (2020-2025)
 Figure 59. Phoenix Pharmaceuticals Revenue Growth Rate in Endogenous Peptide Substances Business (2020-2025)
 Figure 60. Creative Peptides Revenue Growth Rate in Endogenous Peptide Substances Business (2020-2025)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Endogenous Bioactive Peptides Market Research Report 2024
Global Exogenous Bioactive Peptides Market Research Report 2024
Global Peptide Analysis Market Research Report 2025
Global High Pure Peptides Market Research Report 2025
Global Peptide API Market Research Report 2024
Global Silk Peptide Market Research Report 2024
Global Peptide Antibiotics Market Research Report 2025
Peptide Health Products Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GMP Grade Peptide Market Research Report 2024
Global Elastin Peptide Market Research Report 2024
Global Peptide Synthesis Reagents Market Research Report 2025
Global Earthworm Peptide Market Research Report 2024
Global Cyclic Peptide Compounds Market Research Report 2024
Catalog Peptides Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Physiologically Active Peptides Market Research Report 2024
Global Long Chain Modified Peptide Drugs Market Research Report 2024
Global Peptide Screening Service Market Research Report 2025
Global Oral Peptide Therapeutics Market Research Report 2024
Global Peptide Modification Service Market Research Report 2024
Global Peptide Purification System Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions